Colossal Biosciences is a groundbreaking bioscience and genetics company focused on de-extinction, species preservation, and conservation. Utilizing advanced genetic engineering and reproductive technologies, Colossal aims to revive extinct species like the Woolly Mammoth and Thylacine, and protect critically endangered species, ultimately contributing to ecosystem restoration and biodiversity.
Serves as the central hub for research and development, operations, and corporate management. Key laboratory work for genetic engineering, embryology, and early-stage development occurs here.
State-of-the-art laboratories for genomics, gene editing (CRISPR), synthetic biology, advanced sequencing facilities, and cell culture labs designed for complex de-extinction workflows.
Innovative, fast-paced, and mission-driven, attracting top scientists, engineers, and business professionals passionate about breakthrough discoveries in genetics and conservation. Fosters a collaborative environment focused on solving complex biological and ecological challenges.
The Dallas HQ anchors Colossal's ambitious de-extinction projects and serves as a symbol of biotech innovation in Texas. It's central to their strategy of combining cutting-edge science with entrepreneurial execution to achieve unprecedented conservation outcomes.
Colossal Biosciences operates primarily from its headquarters in Dallas, Texas, with significant research and development labs and collaborations in Boston, USA, and Melbourne, Australia. Their work inherently involves global partnerships for sample collection, ecological research, access to genetic data, and potential future rewilding efforts, reflecting the international scope of biodiversity and conservation challenges they address.
110 Record St
Dallas
Texas
USA
Address: Specific address not publicly listed, operations are closely tied with affiliated research institutions and labs in the Boston/Cambridge biotech hub.
Taps into world-leading genomics, synthetic biology, and bioinformatics expertise centered around the Cambridge/Boston academic and biotech innovation hubs.
Address: Collaborates closely with institutions like the University of Melbourne; specific Colossal-owned office/lab address is not broadly public.
Serves as the hub for the Thylacine project due to proximity to historical habitat, local scientific expertise in marsupial biology and conservation, and access to genetic material and related paleontological resources.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Colossal Biosciences' leadership includes:
Colossal Biosciences has been backed by several prominent investors over the years, including:
Colossal Biosciences has actively strengthened its executive team over the past year, notably appointing a new Chief Scientific Officer and a Chief Business & Legal Officer to support its rapid growth and complex scientific and commercial objectives. No major high-profile executive exits have been publicly announced during this period.
Discover the tools Colossal Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Colossal Biosciences does not publicly disclose its official email format, companies in the technology and bioscience sectors commonly use formats like [first_initial][last]@[domain.com] or [first].[last]@[domain.com]. For official inquiries, it is best to use the contact forms or information provided on their website.
first.last@colossal.com
Format
jane.doe@colossal.com
Example
70%
Success rate
Colossal Biosciences Press Release • April 2, 2024
Colossal Biosciences announced the appointment of Dr. Sarah Richardson as its new Chief Scientific Officer. Dr. Richardson will spearhead the company's scientific vision, strategy, and program execution across its de-extinction and conservation projects, bringing extensive experience in synthetic biology and genomics....more
PR Newswire / Colossal Biosciences • March 5, 2024
Colossal Biosciences secured an investment from the United States Innovative Technology Fund (USIT). This funding is aimed at accelerating its pioneering work in genetic engineering and synthetic biology for species restoration and ecosystem preservation, further supporting its Series B extension....more
Colossal Biosciences Press Release • August 29, 2023
Colossal Biosciences announced the formation of its Avian Genomics Group. This specialized team is dedicated to advancing the genetic rescue and de-extinction of the Dodo, focusing on key breakthroughs in avian genetics, including primordial germ cell manipulation and genome editing....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Colossal Biosciences, are just a search away.